Abstract 109P
Background
BM significantly impacts the prognosis of patients (pts) with NSCLC. For pts without targetable gene mutations, treatment options are limited, and the roles of immunotherapy and brain radiotherapy remain controversial. This study aims to examine the effectiveness of first-line immune-based therapies and brain radiotherapy for these pts using real-world data.
Methods
Thirty-nine pts with BM from NSCLC harboring non-sensitizing mutations in EGFR, ALK, or ROS1 were enrolled. The study evaluated the efficacy of first-line immune-based combination therapy and brain radiotherapy. Additionally, it explored the relationship between PD-L1 expression levels in extracranial tissues and intracranial treatment outcomes.
Results
First-line systemic treatment had two groups: one group received immunotherapy plus chemotherapy (I+C, n=21), while the other group received immunotherapy plus antiangiogenic therapy, with or without chemotherapy (I+A±C, n=18). There was no significant difference in intracranial progression-free survival (icPFS), intracranial overall survival (icOS), progression-free survival (PFS), and overall survival (OS) between the two groups (all p > 0.05). Additionally, whether or not to receive brain radiotherapy had no significant effect on survival outcomes (all p > 0.05). There were no significant differences in the intracranial objective response rate (icORR) and intracranial disease control rate (icDCR) between different first-line treatment groups and between those receiving or not receiving brain radiotherapy (all p > 0.05). Analysis of survival results revealed statistically significant differences in icPFS, icOS, PFS, and OS between the PD-L1 high expression group (≥ 50%) and the low expression group (<50%), with p-values of 0.002, 0.003, 0.029, and 0.003, respectively.
Conclusions
Different first-line immunotherapy combinations had no significant effect on the survival outcomes of pts with driver gene-negative BM NSCLC, and brain radiotherapy did not bring additional survival benefits. The PD-L1 TPS expression level in extracranial tissues appears to be a prominent predictor of the efficacy of intracranial immunotherapy.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract